Alendronic acid and Lung infiltration - a phase IV clinical study of FDA data

Summary:

Lung infiltration is reported as a side effect among people who take Alendronic acid (alendronate sodium), especially for people who are female, 50-59 old, have been taking the drug for < 1 month also take Saxagliptin, and have Renal cell carcinoma.

The phase IV clinical study analyzes which people have Lung infiltration when taking Alendronic acid. It is created by eHealthMe based on reports of 18,142 people who have side effects when taking Alendronic acid from the FDA, and is updated regularly.

What is Alendronic acid?

Alendronic acid has active ingredients of alendronate sodium. It is often used in osteoporosis. eHealthMe is studying from 18,408 Alendronic acid users. Check the latest studies of Alendronic acid.

What is Lung infiltration?

Lung infiltration (a substance that normally includes fluid, inflammatory exudates or cells that fill a region of lung) is found to be associated with 1,195 drugs and 1,209 conditions by eHealthMe. Check the latest studies of Lung infiltration.

On Jul, 10, 2026

18,142 people reported to have side effects when taking Alendronic acid.
Among them, 14 people (0.08%) have Lung infiltration.

Could Alendronic acid cause Lung infiltration?

Among these 14 people:

How long have people been on Alendronic acid when they have Lung infiltration? *

What is the gender of people who have Lung infiltration when taking Alendronic acid? *

female: 71.43 %
male: 28.57 %

What is the age of people who have Lung infiltration when taking Alendronic acid? *

What are other drugs people take besides Alendronic acid? *

What are other side effects people have besides Lung infiltration? *

Respiratory Acidosis (respiratory failure or ventilatory failure, causes the ph of blood and other bodily fluids to decrease): 13 people, 92.86%
Diarrhea: 12 people, 85.71%
Hypotension (abnormally low blood pressure): 11 people, 78.57%
Pleural Effusion (water on the lungs): 8 people, 57.14%
Mental Status Changes (general changes in brain function, such as confusion, amnesia (memory loss), loss of alertness, loss of orientation): 7 people, 50.00%
Nausea (feeling of having an urge to vomit): 7 people, 50.00%
Hypophosphataemia (electrolyte disturbance in which there is an abnormally low level of phosphate in the blood): 7 people, 50.00%
Dizziness: 7 people, 50.00%
Peritoneal Haemorrhage (peritoneal bleeding): 7 people, 50.00%
Abdominal Pain: 7 people, 50.00%

What are the existing conditions these people have? *

Renal Cell Carcinoma (a kidney cancer): 6 people, 42.86%
High Blood Pressure: 5 people, 35.71%
Skin Disorder (skin disease): 1 person, 7.14%
Myelodysplastic Syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged): 1 person, 7.14%
Infection: 1 person, 7.14%
Haemosiderosis (general increase in tissue iron stores without associated tissue damage): 1 person, 7.14%
Graft Versus Host Disease (the donated bone marrow or stem cells view the recipient's body as foreign, and the donated cells/bone marrow attack the body): 1 person, 7.14%
Glaucoma (increased fluid pressure in the eye with vision loss): 1 person, 7.14%
Essential Hypertension (primary hypertension): 1 person, 7.14%
Diabetes: 1 person, 7.14%

* Approximation only. Some reports may have incomplete information.

Do you take Alendronic acid and have Lung infiltration?

- Check whether Lung infiltration is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Alendronic acid:

Alendronic acid (18,408 reports)

Browse all side effects of Alendronic acid:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Lung infiltration:

Lung infiltration (1,195 drugs)

Browse all the conditions that are associated with Lung infiltration:

Lung infiltration (1,209 conditions)

Related publications that referenced our studies

Stuckey BG, Sallie R, "Alendronate-induced unmasking or deterioration of coeliac disease: a case series", Osteoporosis International, 2015 Jan .
Lee WY, Sun LM, Lin MC, Liang JA, Chang SN, Sung FC, Muo CH, Kao CH, "A higher dosage of oral alendronate will increase the subsequent cancer risk of osteoporosis patients in Taiwan: a population-based cohort study", PloS one, 2012 Dec .
Stuckey BG, Sallie R, "Alendronate-induced unmasking or deterioration of coeliac disease: a case series", Osteoporosis International, 2015 Jan .
Lee WY, Sun LM, Lin MC, Liang JA, Chang SN, Sung FC, Muo CH, Kao CH, "A higher dosage of oral alendronate will increase the subsequent cancer risk of osteoporosis patients in Taiwan: a population-based cohort study", PloS one, 2012 Dec .

How the study uses the data?

The study uses data from the FDA. It is based on alendronate sodium (the active ingredients of Alendronic acid) and Alendronic acid (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.